{
    "id": 29611,
    "fullName": "RAF1 K106N",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RAF1 K106N lies within the Ras-binding domain of the Raf1 protein (UniProt.org). K106N confers a gain of function to Raf1, as indicated by increased activation of ERK and transformation of cultured cells (PMID: 30867592).",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5894,
        "geneSymbol": "RAF1",
        "terms": [
            "RAF1",
            "c-Raf",
            "CMD1NN",
            "CRAF",
            "NS5",
            "Raf-1"
        ]
    },
    "variant": "K106N",
    "createDate": "03/28/2019",
    "updateDate": "07/24/2019",
    "referenceTranscriptCoordinates": {
        "id": 178984,
        "transcript": "NM_002880",
        "gDna": "chr3:g.12611952T>G",
        "cDna": "c.318A>C",
        "protein": "p.K106N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16573,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Cotellic (cobimetinib) in patients with histiocytic neoplasms resulted in a PET overall response rate of 89% (16/18), with complete response in 72% (13/18) and partial response in 17% (3/18), and resulted in stable disease in 6% (1/18) of patients, including a complete response in a patient with mixed histiocytosis harboring RAF1 K106N (PMID: 30867592; NCT01953926).",
            "molecularProfile": {
                "id": 31684,
                "profileName": "RAF1 K106N"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 60073,
                "name": "lymphatic system cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16583,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cotellic (cobimetinib) inhibited viability of transformed cells expressing RAF1 K106N in culture (PMID: 30867592).",
            "molecularProfile": {
                "id": 31684,
                "profileName": "RAF1 K106N"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14632,
                    "pubMedId": 30867592,
                    "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867592"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31684,
            "profileName": "RAF1 K106N",
            "profileTreatmentApproaches": [
                {
                    "id": 19376,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "RAF1 K106N"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178984,
            "transcript": "NM_002880",
            "gDna": "chr3:g.12611952T>G",
            "cDna": "c.318A>C",
            "protein": "p.K106N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 178985,
            "transcript": "XM_011533974",
            "gDna": "chr3:g.12611952T>G",
            "cDna": "c.318A>C",
            "protein": "p.K106N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 178986,
            "transcript": "XM_005265357",
            "gDna": "chr3:g.12611952T>G",
            "cDna": "c.318A>C",
            "protein": "p.K106N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 178988,
            "transcript": "XM_017006966",
            "gDna": "chr3:g.12611952T>G",
            "cDna": "c.318A>C",
            "protein": "p.K106N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 178987,
            "transcript": "XM_005265355",
            "gDna": "chr3:g.12611952T>G",
            "cDna": "c.318A>C",
            "protein": "p.K106N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}